C
SYRE icon

Covestor’s Spyre Therapeutics SYRE Stock Holding History

Covestor’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
13
+9
+225% +$657 ﹤0.01% 2339
2026
Q1 		$0 Sell
4
-2
-33% -$75 ﹤0.01% 2751
2025
Q4 		$0 Hold
6
– – ﹤0.01% 2721
2025
Q3 		$0 Hold
6
– – ﹤0.01% 2756
2025
Q2 		$0 Buy
6
+2
+50% +$30 ﹤0.01% 2742
2025
Q1 		$0 Hold
4
– – ﹤0.01% 2711
2024
Q4 		$0 Buy
4
+1
+33% +$29 ﹤0.01% 2724
2024
Q3 		$0 Buy
+3
New +$84 ﹤0.01% 2747

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Covestor's SYRE Position: Q2 2026 in Review

Covestor increased its Spyre Therapeutics (SYRE) stake by 225% in Q2 2026, buying an estimated $657 and bringing the position to 13 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Covestor first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Covestor held 13 shares of Spyre Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 9 Spyre Therapeutics shares in Q2 2026, an estimated $657.
  • Spyre Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2339 holding.
  • Covestor first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.